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The controversy regarding the safety of saccharin for human consumption started shortly after
its discovery over 100 years ago and has yet to subside appreciably. The consumption of saccharin,
particularly in North America, began to escalate when the U.S. Food and Drug Administration set
new standards of identity which allowed foods containing artificial sweeteners to be promoted as
"nonnutritive" or "noncaloric" sweeteners for use by the general public. In 1969, when cyclamates
were banned, at least 10 single-generation feeding studies were undertaken with saccharin to more
accurately assess the potential toxicological consequences resulting from the anticipated increase
in its consumption. None of these studies resulted in any overt regulatory action. Subsequently, the
introduction of the two-generation chronic toxicity/carcinogenicity bioassay added a new tool to the
toxicologist's arsenal. Three two-generation studies using saccharin have since been conducted.
The results from these studies clearly show that when rats were exposed to diets containing 5 or
7.5% sodium saccharin from the time of conception to death, an increased frequency of urinary
bladder cancers was found, predominantly in the males. While some study results suggested that
impurities in commercial saccharin or the presence of urinary tract calculi may have been responsi-
ble for the observed bladder tumors, it now appears that these possibilities are highly unlikely. The
mechanism by which saccharin elicited the bladder tumors using the two-generation experiment has
not been ascertained.
Introduction
Saccharin was discovered by accident in 1879 by
Constantin Fahlberg while working in Ira Remsen's
laboratory at Johns Hopkins University (1). Fahl-
berg was investigating the oxidation mechanisms of
toluenesulfonamide, when a compound with which
he was working accidentally splattered on his fin-
gers. Fahlberg, seemingly not the most fastidious of
individuals, failed to wash his hands adequately and
as a consequence, while eating supper that evening
he noted that his bread had a sweet taste which he
traced to the chemical commonly known as sac-
charin (2). In the intervening years, saccharin has
been alternately castigated and approved for hu-
man use by various federal regulatory agencies.
The controversy regarding the safety of saccharin
for human consumption was well underway by 1890
(3) and has not appreciably abated in the inter-
vening years. This melodrama has involved mem-
bers of the scientific community, trade associations,
legislative and regulatory authorities, the press, the
public and even a president of the United States (2).
The most recent tempest was precipitated by the
findings of a two-generation chronic bioassay which
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has been dubbed the Canadian Saccharin Study (4).
This study, which was the third to use the two-
generation bioassay model suggested by the late
Dr. Leo Friedman (5), had followed similar saccharin
studies conducted at the Wisconsin Alumni Re-
search Foundation (WARF) (6) and at the U.S. Food
and Drug Administration (FDA) (7, 8). The ensuing
controversy gave rise to the publication of at least
two books (9, 10), numerous articles in the popular
literature, a plethora of scientific activity, a large
media blitz by several trade associations, as well as
the convening of various panels and conferences to
evaluate and discuss the human consumption of sac-
charin in light of these experimental results
(11-18).
Early History
Some of the first toxicological tests with saccha-
rin were reportedly conducted in France where di-
abetics received 5 g of saccharin per day for 5
months. No harmful effects were noted (19). How-
ever, in 1890, the Commission of the Health Associa-
tion in France decreed saccharin to be "harmful,"
and forbade its manufacture or importation. Several
scientists, especially French hygienists, protested
violently, attempting to refute the assertions that
saccharin was a harmful chemical (3).D. L. ARNOLD
In 1902, Germany placed a complete ban on the
use of saccharin in all foodstuffs except foods in-
tended for diabetics (20). Also in 1902, Dr. Harvey
W. Wiley formed his famous "poison squad" which
consisted of young volunteers who ingested various
foods and food additives to ascertain their effects
upon man. One of the chemicals ingested by this
group was saccharin (21). Based on the findings of
this study, Dr. Wiley attempted without success to
block the commercial use of saccharin as a food ad-
ditive (10).
Subsequently, saccharin was banned in the
United States during 1912 for use in soft drinks and
foods because it was considered to be an adulterant.
However, during World Wars I and II, sugar sup-
plies became so limited that the ban on saccharin
use was temporarily lifted (2).
In 1959, under new standards of identity, the
FDA allowed artificial sweeteners to be used in a
variety of prepared foods which "should be used
only by ... those who must restrict ..." their in-
take of sugar. Subsequently, foods containing artifi-
cial sweeteners were sold not only to people who
had to either restrict their sugar consumption (dia-
betics) or who should avoid excessive caloric intake,
but were also promoted as "nonnutritive" or "non-
caloric" sweeteners for use by the general public (2).
Toxicology Studies
Prior to 1950, several toxicological studies of
short and intermediate duration had been con-
ducted with different species of laboratory animals
and man (3, 22-30). The first chronic/carcinogenic
bioassay using saccharin was undertaken by Fitz-
hugh et al. (31). They conducted a two-year feeding
study in which rats received a control diet (7M, 9F)
or diets containing 1.0% (1OM, 10F) or 5.0% sodium
saccharin (9M, 9F). Saccharin had no apparent effect
upon mortality, hematology or organ weights (liver,
kidney and spleen), but did result in a slight growth
depression in the 5% group. The only significant
pathological change was observed in the 5% group,
where seven animals (sex unspecified) had thoracic
lymphosarcomas; four of these seven rats had ab-
dominal lymphosarcomas as well, which the authors
stated was unusual even though the strain of rats
used were known to have a high spontaneous inci-
dence of lymphosarcomas. The urinary bladder was
not examined histologically. The evaluation of the
pathological changes observed in this study is even
today a matter for debate (13,19).
During the sixties a second chronic/carcinogenic-
ity bioassay was conducted by Lessel (32), who fed
groups of 20 male and 20 female rats diets con-
taining 0, 0.005, 0.05, 0.5 or 5.0% saccharin for 2
years. Another group received 1 mL of a 1% solu-
tion of trypan blue SC every 2 weeks for 1 year as a
positive control. In the 5% and trypan blue groups,
mortality was higher than in the controls. Retarda-
tion of growth was observed in both sexes receiving
the 5% diet despite a greater feed consumption.
One female and four male rats in the 5% saccharin
group had bladder calculi and another male had kid-
ney calculi. The female rat with calculi had an ex-
tensive transitional cell papilloma of the bladder
while another 5% female without calculi had hyper-
plasia and a papilloma. No evidence of nematodes
was found.
In 1969, the use of the artificial sweetener cycla-
mate as a food additive was banned. It therefore
was anticipated that the consumption of saccharin
would increase significantly. Consequently, ten addi-
tional one-generation chronic/carcinogenic bioassays
were undertaken using the rat, mouse and hamster
in such countries as Canada, Germany, Great Bri-
tain, Japan and the United States (11). None of
these studies indicated toxicological consequence of
a nature sufficient to initiate regulatory action.
The one-generation rat feeding study performed
in Canada was conducted by Munro et al. (33) and to
quote the U.S. NRC report dealing with the safety
of saccharin and sodium saccharin in the human
diet, this "... test was carried out with exceptional
care" (34). In this study, groups of 60 male and 60 fe-
male weanling Charles River rats were fed semipur-
ified diets with daily dosages of 0, 90, 270, 810 or
2430 mg of sodium saccharin/kg body weight for 26
months (2500 mg/kg body weight is approximately
equivalent to 5% in the diet). Additional saccharin
was added to each diet to compensate for a mois-
ture content of 1.4%, and the diet was analyzed for
several potential contaminants. The animals were
observed daily for clinical signs of toxicity and peri-
odic cytological examinations of the urine were con-
ducted for the parasite Trichosomoides crassicauda
or its ova, ofwhich none were detected.
Five bladder tumors were observed in the test
animals. In addition, three animals had grossly vis-
ible bladder calculi, and 67 other animals were
found to have bladder calculi which were small
enough to pass through the urethra. The authors
concluded that neither the presence of bladder
calculi nor the saccharin treatments were associated
with the presence of bladder tumors. Various panels
(11,34) and individuals (10) have concurred with the
authors' conclusions, but Reuber (35) concluded from
his review of this study that the results suggested
"that saccharin is most likely carcinogenic for the
urinary bladder."
A rather significant turn of events regarding the
toxicological testing of saccharin occurred at the
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Eighth Annual Meeting of the Society of Toxicol-
ogy, when during a presentation at the Society's
Symposium on the Evaluation of the Safety of Food
Additives and Chemical Residues, the late Dr. Leo
Friedman (5) suggested that "no-effect dose levels
be specifically defined to include that period of an
animal's lifetime from conception to sexual matur-
ity." This suggestion gave rise to the two-
generation chronic/carcinogenic bioassay as we
know it today.
The first two-generation bioassay in which sac-
charin was fed, was conducted under contract at the
Wisconsin Alumni Research Foundation (WARF).
This study (6) had groups of 20 male and 20 female
Sprague-Dawley rats being fed diets containing 0.0,
0.05, 0.5 or 5.0% sodium saccharin produced by the
Remsen-Fahlberg procedure for 14 weeks prior to
mating, as well as during mating and lactation. Fol-
lowing weaning, the Fo generation was killed and
the F1 generation was weaned onto their parents'
diet, which they consumed until the study was
terminated 100 weeks later. Thus, the F, generation
animals were exposed to saccharin and its impuri-
ties during gestation, throughout lactation via the
dam's milk and for the remainder of their lifetime
via the diet.
The authors reported that saccharin had no re-
markable effects upon the reproductive indices, ex-
cepting a depressed pup body weight in the 5.0%
group at weaning. However, after the F1 generation
had been on test for 13 weeks post-weaning, the
growth curves were similar in all groups for the bal-
ance of the study. Neither feed consumption nor
survival was affected by treatment, and the ob-
served hematological changes were considered to
be the result of age and poor health rather than
treatment. The authors suggested that the inci-
dence of tumors was apparently increased by the
consumption of the 5.0% diet. The incidence of
squamous cell carcinomas of the uterus and transi-
tional cell carcinomas of the urinary bladder, were
seen exclusively in the treated groups, with higher
incidence at higher dosage levels.
This study apparently was the first chronic study
undertaken using the two-generation animal model,
which likely enhanced the chances that its results
would be critically evaluated and the deficiencies of
this experimental model emphatically pointed out.
While the U.S. NRC (34) panel recognized the im-
portant implications of using an animal model sys-
tem for testing wherein transplacental exposure
was used, experience and information was limited
regarding: (a) the dose level to which the fetus was
exposed; (b) the developmental stages during organ-
ogenesis; (c) the metabolic capacity of the fetus; (d)
the immune competency of the fetus; and (e) factors
related to fetal pharmacology. Additionally, the
panel went on to point out that factors such as uri-
nary tract stones and parasites, which are known to
cause bladder tumors in rats, were not ruled out as
causative agents in this study.
After the U.S. Food and Drug Administration
(FDA) had an opportunity to review the results of
this study, saccharin was removed from the Gener-
ally Recognized as Safe (GRAS) food additive list.
This action had the legal force of allowing a future
ban on saccharin if there was any question of sac-
charin's safety as a food additive (36).
The second two-generation saccharin feeding
study was conducted by the FDA between 1970 and
1972 as a combination three-generation reproduc-
tion study and two-generation chronic feeding
study. An interim report was presented at the an-
nual Society of Toxicology meeting in 1974 (7), but a
final report did not appear until 1980 (8).
The experimental design consisted of groups of
10 male and 20 female Sprague-Dawley rats being
fed diets containing 0.0, 0.01, 0.1, 1.0, 5.0 or 7.5% so-
dium saccharin, or 1.51% sodium carbonate (giving
a sodium ion concentration equivalent to 5.0% so-
dium saccharin). Another group was fed a diet con-
taining 5.0% calcium cyclamate, which was fed as a
reference compound. A sufficient number of animals
were randomly selected from the F1 litters to give a
total of 48 males and 48 females per test group. In-
terim sacrifices of four animals/sex/group were
made at 14 months and five animals/sex/group at 18
months; but these rats were not part of the original
48 animals/group. The first generation animals were
killed after they produced a second litter.
The authors reported that treatment did not
have any apparent effect on hematological values,
organ weights, or survival and that birth weights of
rats ingesting 5.0 or 7.5% saccharin or 5.0% cycla-
mate were depressed versus controls. Although
some of the initial weight differences were over-
come, these animals had lower body weights
throughout the study. There were several signifi-
cant decreases in average and relative organ
weights, expressed as percentage of body weight,
which the authors attributed to decreases in body
weights. Additionally, there were no dose- or time-
related trends in these results when the data from
the serial sacrifices were included in the analysis.
The most significant pathological findings included
nine urinary bladder neoplasms in the 7.5% group
(7 males, 2 females), one in the 5.0% group (male)
and one in a control male. Three sections of each
bladder (dome, midpoint and bladder neck) from
rats that were on test for more than 18 months,
were examined histologically for evidence of the
bladder parasite Trichosomoides crassicauda. No
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parasites were found, and the authors concluded
that the parasites did not contribute to the develop-
ment of the observed bladder neoplasms. Addition-
ally, the authors concluded that the incidence of
gross calculi was not associated with the observed
neoplasms.
The authors also pointed out that several patholo-
gists or groups of pathologists ineependently re-
viewed tissue sections from the bladder, and while
some differences in diagnosis did occur, the review-
ing groups confirmed that there was a significant in-
crease in urinary bladder neoplasms in the group
receiving 7.5% sodium saccharin.
This study was also criticized along the same
lines as was the WARF study. In addition, the U.S.
NRC (34) panel suggested that the maximum tol-
erated dose (MTD) may have been exceeded for the
5.0 and 7.5% dose groups due to the body weight
suppressions. While the panel commended the inclu-
sion of a group to ascertain what effect the high die-
tary sodium levels attributable to the inclusion of
5.0% sodium saccharin in the diet might have upon
metabolic disposition, they questioned whether or
not carbonate was an appropriate anion.
Before getting into the details of the third two-
generation study, which was conducted by the Ca-
nadian Health Protection Branch, it is appropriate
to point out some of the events happening outside
the animal laboratory and their role in the design of
this study.
The inability of saccharin to induce a significant
tumorigenic response in any one of the one-genera-
tion feeding studies, including the one conducted by
Munro et al. (33), was consistent with the findings of
a number of epidemiological studies that were pub-
lished in the early seventies(37-39). Additionally, the
high dosages of saccharin required to elicit bladder
tumors in the two-generation studies, as well as the
apparent predilection for the second generation
males, resulted in more questions than answers for
the toxicological problem being studied. These find-
ings suggested that an impurity in saccharin might
be responsible for the observed tumorigenic effects.
Studies conducted in the Health Protection Branch
laboratories indicated that o-toluene sulfonamide (o-
TS) was the major impurity in all of the saccharin
samples used in the various long-term feeding stu-
dies (40-42). The concentrations of o-TS ranged from
118 to 6100 ppm in these samples (43) which were
all produced by the Remsen-Fahlberg method.
These and other observations led to the hypothesis
that o-TS, a known inhibitor of carbonic anhydrase
(44, 45), the enzyme involved in the acidification of
urine (46), would increase the excretion of bicarbo-
nate. This action could produce an alkaline urine,
predisposing the animal to urolithiases in the kid-
neys and bladder. Irritation from these stones over
a long period of time could produce hyperplasia and
ultimately tumors (43). A correlation between blad-
der stones and bladder tumors had previously been
found for several experimental situations (47).
As a partial test of his hypothesis, a study was
conducted wherein groups of 24 to 27 untreated
Sprague-Dawley female rates were mated on a one-
to-one basis with untreated males. On day one of
pregnancy, the pregnant females were given the
first of 43 daily doses of o-TS (dosage levels: 0, 40,
100 or 250 mg o-TS/kg/day) in corn oil via gavage.
The pups were then weaned onto diets containing
sufficient amounts of a o-TS to provide the same
dose levels as received by their respective dams.
Three interim kills and a final kill, when the pups
were 105 days old, were performed, at which time
the incidence of renal calculi, bladder calculi and his-
topathological bladder calculi in 21-day-old rats (un-
sexed) and in 105-day-old male and female rats (48).
These findings lent support to the preceding hy-
pothesis.
Health Protection Branch scientists thus pro-
posed that an additional two-generation chronic
feeding study be undertaken to more fully test the
preceding hypothesis. The initial protocol for this
study called for groups of rats to be fed either a
standard commercial chow diet or one containing
graded levels of o-TS. In addition, ammonium chlor-
ide was to be added to the drinking water of one of
the highest o-TS dosed groups to prevent the for-
mation of an alkaline urine (47, 49). Comments on
this experimental protocol were solicited from other
regulatory agencies and a number of internationally
recognized toxicologists, as well as from several in-
dustrial organizations.
Prior to the start of this study, a quantity of sac-
charin produced by the Maumee procedure became
available. This method of saccharin production re-
sults in no detectable levels of o-TS and the total
amount of impurities is less than the Remsen-Fahl-
berg procedure (4, 50). This saccharin was fed to an
additional group of rats at a level of 5% in the low
diet, a level comparable to the highest dose used in
the WARF two-generation study as well as several
conventional one-generation studies (11). In keeping
with the above hypothesis, the latter group was in-
cluded as a "negative" control group.
The final study protocol consisted of groups of 50
male and 50 female (except where noted) Sprague-
Dawley rats being fed one of the following dietary
treatments: control; 2.5 mg o-TS/kg/day; 25 mg
o-TS/kg/day; 250 mg o-TS/kg/day; 250 mg
o-TS/kg/day with 1% NH4Cl in the drinking water
(Fo group size 40 males, 38 females; F1 49 males, 50
females); or 5% sodium saccharin.
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Regarding the conduct of this study (4), the Fo ani-
mals in this two-generation bioassay were 32 days
of age when the study commenced. After 90 days on
test, these animals were mated on a one-to-one basis
within treatment groups. The pups were weaned
onto their parents' diet. Unlike the WARF (6) and
FDA (7, 8) studies, both the Fo and F1 generations
were continued on test for their lifetime. Periodi-
cally, urine samples were filtered and stained by
the Papanicolaou method and examined microscopi-
cally for sediment and exfoliated epithilial cells in
an attempt to diagnose alterations in bladder epi-
thelium. The filters were also examined for ova and
the adult form of Trichosomoides crassicauda. Addi-
tionally, hematological evaluations were conducted
during the course of the study and a limited water
balance study was undertaken with some of the F1
animals. Great care was taken to ensure that this
study was conducted in accordance with the best
toxicological practices employed at that time (51,
52).
Rats from both generations fed diets providing
250 mg o-TS/kg or 250 mg o-TS with 1.0% NH4CI in
the drinking water or containing 5% sodium saccha-
rin had decreased growth rates, but only the former
two groups had a lowered feed consumption. There
were no treatment related effects upon reproduc-
tion, longevity, or hematological parameters. The
animals were free of the bladder parasite Tricho-
somoides crassicauda. While a few animals devel-
oped grossly visible bladder and kidney stones, the
incidence was not treatment related. The incidence
of bladder tumors is shown in Table 1. Tumor diag-
nosis was by concensus among seven independent
pathologists who were not associated with the de-
sign or conduct of the study. There was a statisti-
cally significant increase in the incidence of bladder
tumors in both generations of male rats fed the diet
containing 5% sodium saccharin (p < 0.03, Fo;
p < 0.002, F1); compared to their respective control
groups. An evaluation of individual feed consump-
tion did not reveal any statistical difference
between the amount of feed consumed by animals
which had bladder tumors and those that did not.
The incidence of bladder tumors in all of the other
treatment groups was not significantly different
from that of the respective control groups. A lim-
ited water balance study indicated that the animals
receiving the diets containing sodium saccha-
rin drank approximately twice as much water and
voided twice as much urine as did the control ani-
mals. The urine was also found to be hypotonic.
The complete findings of this study were not
available when several individuals (10, 35) and
panels (11) were reviewing the results of the various
saccharin studies. Consequently, some of the points
Table 1. Incidence of bladder tumors in rats fed diets containing o-TS or sodium saccharin.
Fo generation F, generation
Treatment groups Benign Malignant Benign Malignant
Males
Control 1 0 0 0
2.5 mg o-TS/kg/day 1 0 0 0
25 mg o-TS/kg/day 0 0 0 0
250 mg o-TS/kg/day 1 0 0 0
250 mg o-TS/kg/day
+ 1% NH4C1 0 0 0 0
in drinking water
5% Sodium saccharin 4a,b 3a 4c 8c,d
Females
Control 0 0 0 0
2.5 mg o-TS/kg/day 1 0 2 0
25 mg o-TS/kg/day 0 0 0 0
250 mg o-TS/kg/day 0 0 0 0
250 mg o-TS/kg/day
+ 1° NH4C1 0 0 0 0
in drinking water
5% Sodium saccharin 0 oe 0 2
aNumber of animals with tumors (i.e., benign plus malignant) was significantly higher (p < 0.03) than control. Statistics were
based on numbers of animals surviving until first tumor was observed after 87 weeks on test (No. control = 38F, 36M; No. sac-
charin = 40F, 38M).
bAdditional urinary tract tumors consisted of one animal with a urethral tumor and one animal with a malignant lesion of the
kidney pelvis.
cNumber of animals with malignant tumors (p < 0.002) and total tumors (benign plus malignant; p < 0.01) was significantly higher
than control. Statistics were based on number of animals surviving until first tumor was observed after 67 weeks on test (No.
control = 45F, 42M; No. saccharin = 49F, 45M).
dAdditional urinary tract tumors consisted of one animal with a urethral tumor.
eAdditional urinary tract tumors consisted of two animals with malignant lesions of the kidney pelvis.
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raised by these reviewers have subsequently been
answered with the publication of this study. Gener-
ally speaking, the shortcomings previously referred
to regarding two-generation chronic bioassays are
also applicable to this study. Unfortunately, many of
the criticisms of this experimental model are no
closer to being answered today than they were at
the time the WARF study was conducted (11, 34,
53). The other major criticism of this study, which
was also applicable to the high saccharin dosages
used in the FDA study, was that the MTD would
appear to have been exceeded. While several guide-
lines for the conduct of chronic/carcinogenicity bio-
assays as well as the NCI (54) and IARC (55) guide-
lines suggest that a weight differential greater than
10% between the control and treated groups indi-
cates that the MTD has been exceeded, it has been
pointed out that there was generally a greater
growth differential between control and female rats
receiving high dosages of saccharin than there was
for the male rats in the various saccharin bioassays
(11). Furthermore, there has not been any substan-
tial scientific evidence presented to support the con-
tention that a weight suppression of 10% or greater
renders the animal more or less susceptible to carci-
nogenic responses. However, evidence has existed
for many years that caloric restriction and overnu-
trition/obesity appear respectively to decrease and
increase the incidence of spontaneous tumors (56).
While the evidence from this two-generation
study clearly indicated that o-TS did not have any
carcinogenic potential in this model system,
Schmiihl (57) reported that o-TS may possibly have
a weak carcinogenic effect. His study consisted of
groups of 38 male and 38 female Sprague-Dawley
rats, 3 months of age, fed diets containing 0, 20 or
200 mg o-TS/kg body weight for the remainder of
their lifetimes. The incidence of bladder carcinomas
and bladder papillomas was 0, 0, 1 and 0, 3, 4, re-
spectively. The carcinoma was observed after 759
days (days on test presumably) and the four benign
tumors were found after 861, 877, 878, and 996 days.
In the 20 mg/kg group the papillomas were detected
after 539, 766 and 873 days.
Since Schmihl (57) did not mention the presence
of bladder parasites as he had with a previous study
(58), or bladder calculi, it might be presumed that
neither of these possibilities was involved in the
production of the observed bladder lesions. Conse-
quently, except for the possibility of a difference in
purity of the test chemical, it is not possible at this
time to determine the cause of this apparently con-
flicting result.
Recently, as a component of a larger study,
Hooson et al. (59) administered o-TS in the drinking
water or diet to groups of 63 or 50 female Wistar
SPF weanling rats, respectively, at a level equiva-
lent to 70 mg/kg. No evidence of bladder hyperpla-
sia or neoplasia was observed. One possible contrib-
utory factor to these variable findings was sug-
gested by the authors when they were discussing
interpretation of certain bladder lesions in the rat.
They suggested that part of this problem may be
attributable to the absence of a universally accepted
system for classifying rat bladder neoplasia, assess-
ing invasion of the underlying connective tissue, as
well as incomplete knowledge regarding the behav-
iour of such proliferative lesions. While there is evi-
dence that the bladder neoplasia induced by a vari-
ety of carcinogens are often preceded by hyperplas-
tic lesions that are papillary or nodular in their
growth pattern, it is possible that such lesions are
not progressive, or may even be reversible, in some
situations. Unfortunately, reversible or irreversible
hyperplasias cannot be distinguished histologically
(59).
Observations and Comments
To evaluate and compare studies undertaken
with the same substance, requires detailed informa-
tion concerning the design, conduct, parameters
monitored, how monitoring was performed, and ana-
lytical and statistical procedures. Very seldom is
this information provided with appropriate detail in
journal articles. Nevertheless, Taylor and Morgen-
roth (60) attempted to undertake such an exercise
using five different studies in which saccharin was
fed to rats. Based on the information available to
them, they concluded that: it was not likely that
the strain of rat had a role in the increased inci-
dence of bladder tumors; the basal diet did not ap-
pear to be a factor in the experimental observa-
tions; a dose level of 5% sodium saccharin or
greater is needed in addition to in utero exposure to
produce bladder tumors; the amount of o-TS con-
tamination was not a factor in the findings of blad-
der lesions; and the bladder parasite, Trchosom-
oides crassicauda apparently was not involved in
the findings of the various saccharin studies.
Based on the data currently available, Taylor and
Morgenworth may be correct in their conclusion
that a dose level of 5% sodium saccharin is required
to elicit bladder tumors. However, it should be
pointed out that until the industrially sponsored
two-generation saccharin feeding study, currently in
progress at the International Research and Devel-
opment Corporation, Mattawan, Michigan, was initi-
ated (16), dose levels between 1 and 5% sodium sac-
charin have never been fed to rats during a chronic/
carcinogenicity bioassay. For a substance such as
saccharin, which only elicits a relatively low inci-
dence of bladder lesions when fed at a dietary level
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of 5% and requires a latent period ofapproximately
two years, one might not expect an appreciable inci-
dence of bladder lesions attributable to saccharin at
dietary levels of 1%, unless the number of test ani-
mals in the group exceeds 50 and the survivability
after two years on test is excellent. The experimen-
tal design of the aforementioned industry-sponsored
study does include increasing the number of
animals in each test group as the doses are lowered
(16). Consequently, this study may well provide
evidence that saccharin will elicit bladder tumors in
male offspring at dose levels below 5% using the
two-generation model.
Before proceeding, a few additional comments
concerning the conclusions of Taylor and Morgen-
roth (60) are not impertinent. All three of the two-
generation saccharin feeding studies and the two
one-generation feeding studies conducted by Munro
et al. (33) and by Homburger (61), all used Sprague-
Dawley rats. While the latter two studies were con-
sidered to be negative, it has been suggested it may
be "more prudent to conclude that these studies
were not conducted adequately than that they were
negative" (11). In retrospect, based primarily on the
first-generation findings of the two-generation HPB
study, and the observation of Fukushima and Cohen
(62), there appears to be some evidence to suggest
that the one-generation studies were either not sen-
sitive enough to detect the carcinogenic potential of
saccharin, in part attributable to the age of the ani-
mal when the study was initiated, or the procedures
used to evaluate the pathological changes of the
bladder and urinary tract elicited by saccharin were
not appropriate. A countering argument is that the
statistically significant (p > 0.03) increased incidence
of bladder tumors seen in the first generation of the
two-generation HPB study (4) may have been due to
random chance. However, the mean latent period
for saccharin to elicit bladder tumors in the rat is
approximately 90 to 100 weeks (4, 7, 8, 63), sug-
gesting that the improved survivability of the test
animals in the two-generation HPB study (4) en-
hanced the possibility of observing tumors in the
saccharin treated rats. For additional comments and
analysis, the reader is referred to the literature (10,
11, 35).
One point which has not been adequately ad-
dressed concerns whether the incidence of bladder
tumors in the two-generation saccharin studies may
have a genetic component as well as a test chemical
component. Specifically, in the WARF (6) and HPB
(4) studies, the Fo animals were mated on a one-to-
one basis, while in the FDA (7, 8) study, one male
was mated with two females. Grice et al. (53) have
found that the inter-litter variation for styrene, sac-
charin and amaranth exposure was statistically sig-
nificant whereas the inter-litter differences re-
garding transplacental exposure were more homo-
geneous. Based on a limited data base, Grice et al.
suggested that as a result of inter-litter differences
in both transplacental exposure and/or exposure
during lactation as well as genealogical considera-
tions, the litter rather than the individual pup may
be the more appropriate unit for purposes of statis-
tical analysis.
Concluding Remarks
Any review of the toxicological data concerning
saccharin would convince any skeptic that saccharin
is one of the most thoroughly tested food additives
ever consumed. However, as the adage goes, the
more one knows the more one realizes how much
one does not know. One of the biggest questions
that still confronts the scientific and regulatory
communities regarding saccharin is the precise
mechanism by which saccharin elicits bladder tu-
mors in laboratory rats. While the scientific commu-
nity has dubbed saccharin an epigenetic (64) or sec-
ondary carcinogen (65), the North American regula-
tory agencies currently do not distinguish between
electrophilic carcinogens and those which elicit tu-
mors by any other mechanism. However, as pointed
out by Truhaut (65), it should be possible to estab-
lish a threshold or no-effect level for chemicals that
produce tumors by mechanisms other than electro-
philic interaction with cellular macromolecules.
The strongest evidence that saccharin is a carcin-
ogen involves the two-generation bioassay model,
regarding which there is limited experience and
which raises many questions to which answers pres-
ently do not exist (13, 34, 53). While some may view
the two-generation bioassay as a more sensitive an-
alytical tool for toxicological testing and/or a very
practical toxicological testing model, particularly re-
garding saccharin, our experience with hexachloro-
benzene in the two-generation bioassay (Arnold et
al., unpublished data) does not suggest that it is
more sensitive per se, particularly regarding can-
cer. However, studies presently underway in the
United States regarding the testing of a number of
food colors using the two-generation bioassay, will
provide a better insight into this question.
The role which impurities may play in the toxico-
logical effects observed as a result of exposure to
saccharin, cannot be completely dismissed. How-
ever, there is no compelling evidence that the levels
of impurities normally found in commercial saccha-
rin (66) contribute to the observed carcinogenicity of
saccharin. The fact that several batches of Remsen-
Fahlberg-produced saccharin were used in the two-
generation WARF (6) and FDA (7, 8) studies, while
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Maumee-produced saccharin was used in the HPB
study (4), would support such a conclusion. If an im-
purity were responsible for the carcinogenic effect
of saccharin, it would have to be an extremely po-
tent bladder carcinogen.
Saccharin is not metabolized to any significant ex-
tent (67-71), if at all (72- 76); it is nucleophilic (64) and
does not bind to rat liver or bladder DNA (77), but it
does suppress primary humoral antibody produc-
tion in the rat (78). At dosages of 5% and above,
several pharmacokinetic changes are also induced in
the rat (79). Saccharin, therefore, probably does not
act as a typical chemical carcinogen according to the
theory that most, if not all, ultimate carcinogens are
strong electrophilic agents. (80). Consequently, we
had initially proposed that it was possible that sac-
charin administered at the dietary level used in the
two-generation studies may have elicited bladder
tumors by some type of physical mechanism. While
there was some initial support for this suggestion
(4), subsequent studies in our laboratory were not
supportive of such a hypothesis (16). Several of the
subsequent authors will discuss evidence for other
possible mechanisms by which saccharin may give
rise to tumors.
The author thanks Mr. A. Peterkin for his assistance in pre-
paring the manuscript, and Mrs. T. Kelly for her typing assis-
tance.
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